4.3 Review

Fructose vs. glucose and metabolism: do the metabolic differences matter?

Journal

CURRENT OPINION IN LIPIDOLOGY
Volume 25, Issue 1, Pages 8-19

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOL.0000000000000042

Keywords

cardiometabolic risk; sugars; systematic review and meta-analysis; trials

Funding

  1. Canadian Institutes of health Research (CIHR)
  2. Calorie Control Council
  3. The Coca-Cola Company
  4. Pulse Canada
  5. The International Tree Nut Council Nutrition Research & Education Foundation
  6. American Heart Association (AHA)
  7. American College of Physicians (ACP)
  8. American Society for Nutrition (ASN)
  9. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH)
  10. Canadian Diabetes Association (CDA)
  11. Canadian Nutrition Society (CNS)
  12. Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD)
  13. International Life Sciences Institute (ILSI) North America
  14. International Life Sciences Institute (ILSI) Brazil
  15. University of South Carolina
  16. Canadian Sugar Institute
  17. Abbott Laboratories
  18. Canadian Institutes of Health Research (CIHR) Knowledge Synthesis grant [102078]
  19. Province of Ontario Graduate Scholarships
  20. Canadian Institutes of Health Research (CIHR)-Fredrick Banting and Charles Best Canada Graduate Scholarship
  21. Banting and Best Diabetes Centre (BBDC)-Novo Nordisk Studentship
  22. CIHR

Ask authors/readers for more resources

Purpose of reviewFructose is seen as uniquely contributing to the pandemics of obesity and its cardiometabolic complications. Much of the evidence for this view derives from the unique biochemical, metabolic, and endocrine responses that differentiate fructose from glucose. To understand whether these proposed mechanisms result in clinically meaningful modification of cardiovascular risk in humans, we update a series of systematic reviews and meta-analyses of controlled feeding trials to assess the cardiometabolic effects of fructose in isocaloric replacement for glucose.Recent findingsA total of 20 controlled feeding trials (n=344) have investigated the effect of fructose in/on cardiometabolic endpoints. Pooled analyses show that although fructose may increase total cholesterol, uric acid, and postprandial triglycerides in isocaloric replacement for glucose, it does not appear to be any worse than glucose in its effects on other aspects of the lipid profile, insulin, or markers of nonalcoholic fatty liver disease. It may also have important advantages over glucose for body weight, glycemic control, and blood pressure.SummaryDepending on the cardiometabolic endpoint in question, fructose has variable effects when replacing glucose. In the absence of clear evidence of net harm, there is no justification to replace fructose with glucose in the diet.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available